Concepedia

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer

Bianca van Veggel, Juliana F. Vilacha Madeira R Santos, Sayed M.S. Hashemi, Marthe S. Paats, Kim Monkhorst, Daniëlle A.M. Heideman, Matthew R. Groves, Teodora Radonic, Egbert F. Smit, Ed Schuuring,

Lung Cancer · 2019 · 93 citations · 12 references

DOIFull text

Open access

Concepts

References

12

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

Hiroyuki Yasuda, Eunyoung Park, Cai-Hong Yun et al. · Science Translational Medicine · 2013 · 565 citations · Full text

, , +12

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Jacqulyne Robichaux, Yasir Y. Elamin, Zhi Tan et al. · Nature Medicine · 2018 · 455 citations

, , +14

Impact of <i>TP53</i> Mutations on Outcome in <i>EGFR</i> -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

Matteo Canale, Elisabetta Petracci, Angelo Delmonte et al. · Clinical Cancer Research · 2016 · 297 citations · Full text

, , +16

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

Jonathan W. Riess, David R. Gandara, Garrett M. Frampton et al. · Journal of Thoracic Oncology · 2018 · 229 citations

, , +11

<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer

Toshiyuki Hirano, Hiroyuki Yasuda, Tetsuo Tani et al. · Oncotarget · 2015 · 158 citations · Full text

, , +13